T. Rowe Price Associates
OKUR

T. Rowe Price Associates’s OnKure Therapeutics OKUR Stock Holding History

T. Rowe Price Associates’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$98K Buy
+21,481
New +$92.2K ﹤0.01% 3149

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates's OKUR Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in OnKure Therapeutics (OKUR) in Q2 2026: 21,481 shares worth $98K. The stake represents ﹤0.01% of the portfolio and ranks #3149 among its holdings.

75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • T. Rowe Price Associates held 21,481 shares of OnKure Therapeutics worth $98K as of Q2 2026.
  • OnKure Therapeutics was a new T. Rowe Price Associates position in Q2 2026.
  • OnKure Therapeutics made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #3149 holding.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.